Market atlas / NAD+ precursors / Nicotinamide riboside

Nicotinamide riboside (NAD+ precursor)

traditional-to-validatedsmall-moleculenad-precursor● nad-levels

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCH+3 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	consumer	not dated	not published
UK	RCT	2016-06-01	not published
CH	signal	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Nicotinamide riboside, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Percent of participants who receive >75% of scheduled doses.	US
Percent of participants experiencing a CTCAE 5.0 grade 3 or higher related to the study drug	US
Blood Pressure	US
Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS)	US
Changes in plasma NAD+ levels	US
Changes in 6-Minute Walk Test Performance	US
Complications	US
Within-Participant Change in Peak V02 (Maximal Oxygen Uptake on Cardiopulmonary Exercise Testing)	US
Thigh Intraepidermal Nerve Fiber Density	US
Heart rate	US

Connections

Trajectory

2016

MarketUK: rct (clinical trials (highest phase 2))

NCT02950441 · machine-extracted

2019

Relatedshares a mechanism with Nmn

NCT03821623 · machine-extracted

2019

ProfileNicotinamide riboside (NAD+ precursor)

NCT03821623 · machine-extracted

2019

MarketUS: rct (clinical trials (highest phase 2))

NCT03821623 · machine-extracted

2026

MarketUS: consumer (US dietary supplement (DSHEA), not FDA-approved as a drug)

DSLD:333430 · machine-extracted

2026

MarketCH: signal (clinical trials (highest phase ?))

NCT05517122 · machine-extracted

Get into the weeds: raw observations + provenance

nr_uk  2026-06-29  kind=geography_stage  verify=M
   Nicotinamide riboside: UK phase 2 trials [NCT02950441]
   source NCT02950441  https://clinicaltrials.gov/study/NCT02950441

nr_edge_nmn  2026-06-29  kind=edge  verify=M
   both NAD+ precursors
   source NCT03821623  https://clinicaltrials.gov/study/NCT03821623

nr_facets  2026-06-29  kind=facets  verify=M
   NR facets
   source NCT03821623  https://clinicaltrials.gov/study/NCT03821623

nr_us_trial  2026-06-29  kind=geography_stage  verify=M
   Nicotinamide riboside: US phase 2 trials [NCT03821623]
   source NCT03821623  https://clinicaltrials.gov/study/NCT03821623

nr_us_consumer  2026-06-29  kind=geography_stage  verify=M
   Nicotinamide riboside (e.g. Niagen) sold as a US dietary supplement
   source DSLD:333430  https://dsld.od.nih.gov/label/333430

ctsearch__CH__dev_nr  2026-07-10  kind=geography_stage  verify=M
   nicotinamide riboside: 1 registered trial(s) in CH, highest phase ? [NCT05517122]
   source NCT05517122  https://clinicaltrials.gov/study/NCT05517122